Skip to main content
| News

Lonza set to manufacture coronavirus drug for Humanigen

15.09.2020

The Basel-based pharmaceutical supplier Lonza is supporting the US firm Humanigen in the development of a potential coronavirus therapeutic. Lonza is also cooperating with the biotech company Moderna on the development of a promising coronavirus vaccine.

Lonza headquarter in Basel (img: Lonza)

Lonza has secured a contract from the US cancer and infection specialists Humanigen, a press release reveals. Together, the two companies are planning to expand production capacities to manufacture the product candidate lenzilumab.

The drug developed by Humanigen is currently being tested in terms of its suitability to treat the coronavirus. According to information in the press release, it could receive an Emergency Use Authorization before the end of this year. Humanigen is keen to start commercial production activities of the drug at Lonza production facilities in 2021.

“We are ramping up our manufacturing efforts for lenzilumab, our lead drug candidate, and this collaboration with Lonza, a global manufacturing leader with expertise in technology transfer and an established track record of working with regulatory bodies for approved and commercialized products, comes at a crucial time to meet production demand for COVID-19 therapeutics this winter.”, comments Cameron Durrant, CEO of Humanigen, in the press release.

Humanigen is not the first company to make use of Lonza’s expertise in the production of a potential coronavirus therapeutic. Moderna is also working together with Lonza on the development of its coronavirus vaccine candidate. The US biotech company recently established a Swiss subsidiary, which is located close to Lonza in Basel.

The vaccine candidate from Moderna is regarded as particularly promising. The Swiss government has already signed a contract with Moderna allowing it to acquire 4.5 million doses, provided of course that the vaccine candidate is awarded authorization for the Swiss market.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

South Korean pharma firms show interest in the Basel Area

Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...

Read More
Gamma Technologies acquires ProFEMAG portfolio
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

Gamma Technologies acquires ProFEMAG portfolio

The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based...

Read More
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Databaum establishes headquarters in Basel

Databaum is establishing its headquarters in Basel and plans to grow from its location there. The startup provides the agricultural...

Read More
Clinerion launches patient information platform
Basel Area Business & Innovation, Digital Health, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion launches patient information platform

Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

New innovation campus opens in the Basel Area

The Main Campus of the Switzerland Innovation Park Basel Area was officially opened on October 29. In his speech, Federal...

Read More
Sumitovant acquires all shares in Myovant
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sumitovant acquires all shares in Myovant

Sumitovant is in the process of making Basel-based Myovant Sciences a wholly owned subsidiary by acquiring a 100 percent shareholding...

Read More
1 2 3 59

Do you have a question? We'd like to hear from you.